Exact Mass: 373.1538674
Exact Mass Matches: 373.1538674
Found 500 metabolites which its exact mass value is equals to given mass value 373.1538674,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Prochlorperazine
C20H24ClN3S (373.13793740000006)
Prochlorperazine is only found in individuals that have used or taken this drug. It is a phenothiazine antipsychotic used principally in the treatment of nausea; vomiting; and vertigo. It is more likely than chlorpromazine to cause extrapyramidal disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)The mechanism of action of prochlorperazine has not been fully determined, but may be primarily related to its antidopaminergic effects. Prochlorperazine blocks the D2 somatodendritic autoreceptor, resulting in the blockade of postsynaptic dopamine receptors in the mesolimbic system and an increased dopamine turnover. Prochlorperazine also has anti-emetic effects, which can be attributed to dopamine blockade in the chemoreceptor trigger zone. Prochlorperazine also blocks anticholinergic and alpha-adrenergic receptors, the blockade of alpha(1)-adrenergic receptors resulting in sedation, muscle relaxation, and hypotension. N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AB - Phenothiazines with piperazine structure D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent > C740 - Phenothiazine D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents D005765 - Gastrointestinal Agents > D000932 - Antiemetics
Hasubanonine
C21H27NO5 (373.18891320000006)
violaceinic acid
C21H15N3O4 (373.10625100000004)
A pyrrolecarboxylic acid that is pyrrole-2-carboxylic acid which is substituted at position 3 by a 3-hydroxyindol-3-yl group at at position 5 by a 5-hydroxyindol-3-yl group.
Spirotetramat
C21H27NO5 (373.18891320000006)
D010575 - Pesticides > D007306 - Insecticides D016573 - Agrochemicals CONFIDENCE standard compound; INTERNAL_ID 686; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9268; ORIGINAL_PRECURSOR_SCAN_NO 9267 CONFIDENCE standard compound; INTERNAL_ID 686; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9334; ORIGINAL_PRECURSOR_SCAN_NO 9333 CONFIDENCE standard compound; INTERNAL_ID 686; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9232; ORIGINAL_PRECURSOR_SCAN_NO 9231 CONFIDENCE standard compound; INTERNAL_ID 686; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9326; ORIGINAL_PRECURSOR_SCAN_NO 9325 CONFIDENCE standard compound; INTERNAL_ID 686; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9276; ORIGINAL_PRECURSOR_SCAN_NO 9275 CONFIDENCE standard compound; INTERNAL_ID 686; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9319; ORIGINAL_PRECURSOR_SCAN_NO 9318
Olopatadine Hydrochloride
C21H24ClNO3 (373.14446240000007)
D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents D018926 - Anti-Allergic Agents Olopatadine hydrochloride (ALO4943A) is a histamine blocker used to treat allergic conjunctivitis. Target: Histamine Receptor Olopatadine hydrochloride (ALO4943A) is one of the second-generation histamine H1 receptor antagonists that are treated for allergic disorders. Olopatadine hydrochloride (ALO4943A) significantly inhibited the ear swelling and the increased production of IL-4, IL-1beta, IL-6, GM-CSF and NGF in the lesioned ear [1]. Olopatadine hydrochloride (ALO4943A) was highly and rapidly absorbed in healthy human volunteers. The urinary excretion of Olopatadine hydrochloride (ALO4943A) accounted for not less than 58\% and the contribution of metabolism was considerably low in the clearance of olopatadine in humans. Olopatadine hydrochloride (ALO4943A) is one of the few renal clearance drugs in antiallergic drugs. Olopatadine hydrochloride (ALO4943A) was shown to be useful for the treatment of allergic rhinitis and chronic urticaria in double-blind clinical trials [2]. Olopatadine hydrochloride (ALO4943A) inhibits histamine release in a concentration-dependent fashion (IC50 = 559 microM) from human conjunctival mast cell preparations in vitro. Passive anaphylaxis in guinea pig conjunctiva was attenuated by Olopatadine hydrochloride (ALO4943A) applied 30 min prior to intravenous or topical ocular antigen challenge (ED50 values 0.0067\% and 0.0170\%, w/v, respectively) [3].
Deferasirox
C21H15N3O4 (373.10625100000004)
Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. It is the first oral medication approved in the USA for this purpose. V - Various > V03 - All other therapeutic products > V03A - All other therapeutic products > V03AC - Iron chelating agents D064449 - Sequestering Agents > D002614 - Chelating Agents > D007502 - Iron Chelating Agents
N-Jasmonoyltyrosine
C21H27NO5 (373.18891320000006)
N-Jasmonoyltyrosine is found in pulses. N-Jasmonoyltyrosine is a constituent of the flowers of Vicia faba. Constituent of the flowers of Vicia faba. N-Jasmonoyltyrosine is found in pulses.
Prasugrel
Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thereby inhibiting ADP-mediated platelet activation and aggregation. Prasugrel inhibits ADP-mediated platelet aggregation more rapidly, more consistently and to a greater extent (at least 30\\\%) than clopidogrel. The increased potency of prasugrel appears to be due to more efficient conversion to its active metabolite. The relationship, however, between increased platelet aggregation and clinical response has not been determined. Prasugrel carries a higher risk of bleed compared to clopidogrel, which may be a result of its higher potency. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AC - Platelet aggregation inhibitors excl. heparin C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent > C190801 - P2Y12 Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[1].
para-hydroxyrosiglitazone
C18H19N3O4S (373.10962140000004)
para-hydroxyrosiglitazone is a metabolite of rosiglitazone. Rosiglitazone is an antidiabetic drug in the thiazolidinedione class of drugs. It works as an insulin sensitizer, by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin. It is marketed by the pharmaceutical company GlaxoSmithKline (GSK) as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Annual sales peaked at approximately $2.5bn in 2006, but declined after reports of adverse effects. (Wikipedia)
ortho-hydroxyrosiglitazone
C18H19N3O4S (373.10962140000004)
ortho-hydroxyrosiglitazone is a metabolite of rosiglitazone. Rosiglitazone is an antidiabetic drug in the thiazolidinedione class of drugs. It works as an insulin sensitizer, by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin. It is marketed by the pharmaceutical company GlaxoSmithKline (GSK) as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Annual sales peaked at approximately $2.5bn in 2006, but declined after reports of adverse effects. (Wikipedia)
(1-(5-Fluoropentyl)-1H-indol-3-yl)(4-methylnaphthalen-1-yl)methanone
2-Hydroxy-3-methoxy-6beta-naltrexol
C21H27NO5 (373.18891320000006)
Clebopride
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03F - Propulsives > A03FA - Propulsives D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist D005765 - Gastrointestinal Agents > D000932 - Antiemetics D002491 - Central Nervous System Agents
Motesanib
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
N-Desmethyltrimebutine
C21H27NO5 (373.18891320000006)
(2s,5s)-2-Methyl-5-(4-(5-methyl-2-(p-tolyl)oxazol-4-yl)butyl)-1,3-dioxane-2-carboxylic acid
C21H27NO5 (373.18891320000006)
p-Chlorodisopyramide
C21H28ClN3O (373.19207880000005)
Ritobegron
C21H27NO5 (373.18891320000006)
Hydroxydesmethyltetrahydropiperine sulfate
C16H23NO7S (373.11951680000004)
Jatrorrhizine
C20H20NO4+.Cl- (373.1080790000001)
Jatrorrhizine chloride is an alkaloid isolated from?Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities[1]. Jatrorrhizine chloride is a potent and orally active inhibitor of?AChE?(IC50=872 nM) over >115-fold selectivity for BuChE[2]. Jatrorrhizine chloride reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters[3]. Jatrorrhizine chloride is an alkaloid isolated from?Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities[1]. Jatrorrhizine chloride is a potent and orally active inhibitor of?AChE?(IC50=872 nM) over >115-fold selectivity for BuChE[2]. Jatrorrhizine chloride reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters[3]. Jatrorrhizine chloride is an alkaloid isolated from?Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities[1]. Jatrorrhizine chloride is a potent and orally active inhibitor of?AChE?(IC50=872 nM) over >115-fold selectivity for BuChE[2]. Jatrorrhizine chloride reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters[3].
3-epi-2,18-Dimethoxyschelhammericine
C21H27NO5 (373.18891320000006)
diethyl 4-(4-hydroxy-3-methoxyphenyl)-2,6-dimethylpyridine-3,5-dicarboxylate
(1-(5-Fluoropentyl)-1H-indol-3-yl)(4-methylnaphthalen-1-yl)methanone
2-acetoxyisotaxodine|O2-Ac-2-Hydroxyisotaxodine
C21H27NO5 (373.18891320000006)
acetic acid (2R,3R,4R,5R)-4,5-diacetoxy-2-acetoxymethyl-1-acetyl-piperidin-3-yl ester|peracetyl-1-deoxymannonojirimycin
pyrrole-2-carboxylic acid 13-hydroxy-11-oxo-dodecahydro-7,14-methano-dipyrido[1,2-a;1,2-e][1,5]diazocin-2-yl ester
C20H27N3O4 (373.20014620000006)
(E)-N-(4-hydroxy-3,5-dimethoxyphenethyl)-3-(4-hydroxy-3-methoxyphenyl)acrylamide|hibiscusamide
6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-3,4-dihydro-1H-isoquinoline
C21H27NO5 (373.18891320000006)
2,3-methanediyldioxy-4,6beta-dimethoxy-17-methyl-10a-homo-morphin-8(14)-en-7beta-ol|Alkaloid CC-2|alkaloid CC-2 (Colchicum cornigerum)
C21H27NO5 (373.18891320000006)
(2Z)-5-{[(2E,4E,6E)-7-(2-thienyl)-2,4,6-heptatrienoyl]amino}-2-pentenyl 3-methylbutanoate
C21H27NO3S (373.17115520000004)
ent-4,5alpha-epoxy-2,3,6beta-trimethoxy-17-methyl-10a-homo-morphin-8(14)-en-7beta-ol|Kreysiginin|Kreysiginine
C21H27NO5 (373.18891320000006)
Cystodytin E
An alkaloid that is an enamide obtained by the formal condensation of tiglic acid with 6-(2-amino-1-hydroxyethyl)-4H-pyrido[2,3,4-kl]acridin-4-one. It is isolated from the Okinawan marine tunicate Cystodytes dellechiajei and exhibits cytotoxicity against human epidermoid carcinoma KB cells
calpurmeninepyrrolecarboxylic acid
C20H27N3O4 (373.20014620000006)
(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-(3-methyl-5-oxo-1-phenyl-1,5-dihydro-pyrazol-4-yliden)-amin|(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-(3-methyl-5-oxo-1-phenyl-1,5-dihydro-pyrazol-4-yliden)-amine|1,5,5-trimethyl-2,2-diphenyl-1,2,2,4-tetrahydro-4,4-azanylylidene-bis-pyrazol-3-one|Methylrubazonsaeure
Cystodytin D
An alkaloid that is an enamide obtained by the formal condensation of 3-methylbut-2-enoic acid with 6-(2-amino-1-hydroxyethyl)-4H-pyrido[2,3,4-kl]acridin-4-one. It is isolated from the Okinawan marine tunicate Cystodytes dellechiajei and exhibits cytotoxicity against human epidermoid carcinoma KB cells.
(3-Oxo-2-pentylcyclopentyl) acetic acid
C18H23N5O4 (373.17499580000003)
Zoolobelin
C22H28ClNO2 (373.18084580000004)
Lobeline (α-Lobeline) hydrochloride is a brain-penetrant nicotinic receptor agonist. Lobeline hydrochloride increases dopamine (DA) release by inhibiting DA uptake into synaptic vesicles, and altering presynaptic DA storage. Lobeline hydrochloride is effective in smoking cessation[1][2]. Lobeline hydrochloride, a nicotinic receptor agonist, acting as a potent antagonist at both α3β2 and α4β2 neuronal nicotinic receptor subtypes.
Jatrorrhizine
C20H20ClNO4 (373.1080790000001)
Jatrorrhizine chloride is an alkaloid isolated from?Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities[1]. Jatrorrhizine chloride is a potent and orally active inhibitor of?AChE?(IC50=872 nM) over >115-fold selectivity for BuChE[2]. Jatrorrhizine chloride reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters[3]. Jatrorrhizine chloride is an alkaloid isolated from?Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities[1]. Jatrorrhizine chloride is a potent and orally active inhibitor of?AChE?(IC50=872 nM) over >115-fold selectivity for BuChE[2]. Jatrorrhizine chloride reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters[3]. Jatrorrhizine chloride is an alkaloid isolated from?Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities[1]. Jatrorrhizine chloride is a potent and orally active inhibitor of?AChE?(IC50=872 nM) over >115-fold selectivity for BuChE[2]. Jatrorrhizine chloride reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters[3].
Deferasirox
C21H15N3O4 (373.10625100000004)
V - Various > V03 - All other therapeutic products > V03A - All other therapeutic products > V03AC - Iron chelating agents D064449 - Sequestering Agents > D002614 - Chelating Agents > D007502 - Iron Chelating Agents CONFIDENCE standard compound; EAWAG_UCHEM_ID 2842 EAWAG_UCHEM_ID 2842; CONFIDENCE standard compound
prochlorperazine
C20H24ClN3S (373.13793740000006)
N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AB - Phenothiazines with piperazine structure D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent > C740 - Phenothiazine D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents D005765 - Gastrointestinal Agents > D000932 - Antiemetics
8-2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-guanine
Ala Ala Asn Val
Ala Ala Val Asn
Ala Gly Ile Asn
Ala Gly Leu Asn
Ala Gly Asn Ile
Ala Gly Asn Leu
Ala Gly Gln Val
Ala Gly Val Gln
Ala Ile Gly Asn
Ala Ile Asn Gly
Ala Leu Gly Asn
Ala Leu Asn Gly
Ala Asn Ala Val
Ala Asn Gly Ile
Ala Asn Gly Leu
Ala Asn Ile Gly
Ala Asn Leu Gly
Ala Asn Val Ala
Ala Gln Gly Val
Ala Gln Val Gly
Ala Val Ala Asn
Ala Val Gly Gln
Ala Val Asn Ala
Ala Val Gln Gly
Gly Ala Ile Asn
Gly Ala Leu Asn
Gly Ala Asn Ile
Gly Ala Asn Leu
Gly Ala Gln Val
Gly Ala Val Gln
Gly Gly Ile Gln
Gly Gly Leu Gln
Gly Gly Gln Ile
Gly Gly Gln Leu
Gly Ile Ala Asn
Gly Ile Gly Gln
Gly Ile Asn Ala
Gly Ile Gln Gly
Gly Leu Ala Asn
Gly Leu Gly Gln
Gly Leu Asn Ala
Gly Leu Gln Gly
Gly Asn Ala Ile
Gly Asn Ala Leu
Gly Asn Ile Ala
Gly Asn Leu Ala
Gly Asn Pro Ser
Gly Asn Ser Pro
Gly Pro Asn Ser
Gly Pro Ser Asn
Gly Gln Ala Val
Gly Gln Gly Ile
Gly Gln Gly Leu
Gly Gln Ile Gly
Gly Gln Leu Gly
Gly Gln Val Ala
Gly Ser Asn Pro
Gly Ser Pro Asn
Gly Val Ala Gln
Gly Val Gln Ala
Ile Ala Gly Asn
Ile Ala Asn Gly
Ile Gly Ala Asn
Ile Gly Gly Gln
Ile Gly Asn Ala
Ile Gly Gln Gly
Ile Asn Ala Gly
Ile Asn Gly Ala
Ile Gln Gly Gly
Leu Ala Gly Asn
Leu Ala Asn Gly
Leu Gly Ala Asn
Leu Gly Gly Gln
Leu Gly Asn Ala
Leu Gly Gln Gly
Leu Asn Ala Gly
Leu Asn Gly Ala
Leu Gln Gly Gly
Asn Ala Ala Val
Asn Ala Gly Ile
Asn Ala Gly Leu
Asn Ala Ile Gly
Asn Ala Leu Gly
Asn Ala Val Ala
Asn Gly Ala Ile
Asn Gly Ala Leu
Asn Gly Ile Ala
Asn Gly Leu Ala
Asn Gly Pro Ser
Asn Gly Ser Pro
Asn Ile Ala Gly
Asn Ile Gly Ala
Asn Leu Ala Gly
Asn Leu Gly Ala
Asn Pro Gly Ser
Asn Pro Ser Gly
Asn Ser Gly Pro
Asn Ser Pro Gly
Asn Val Ala Ala
Pro Gly Asn Ser
Pro Gly Ser Asn
Pro Asn Gly Ser
Pro Asn Ser Gly
Pro Ser Gly Asn
Pro Ser Asn Gly
Gln Ala Gly Val
Gln Ala Val Gly
Gln Gly Ala Val
Gln Gly Gly Ile
Gln Gly Gly Leu
Gln Gly Ile Gly
Gln Gly Leu Gly
Gln Gly Val Ala
Gln Ile Gly Gly
Gln Leu Gly Gly
Gln Val Ala Gly
Gln Val Gly Ala
Ser Gly Asn Pro
Ser Gly Pro Asn
Ser Asn Gly Pro
Ser Asn Pro Gly
Ser Pro Gly Asn
Ser Pro Asn Gly
Val Ala Ala Asn
Val Ala Gly Gln
Val Ala Asn Ala
Val Ala Gln Gly
Val Gly Ala Gln
Val Gly Gln Ala
Val Asn Ala Ala
Val Gln Ala Gly
Val Gln Gly Ala
Clebopride
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03F - Propulsives > A03FA - Propulsives D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist D005765 - Gastrointestinal Agents > D000932 - Antiemetics D002491 - Central Nervous System Agents
CS-747
B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AC - Platelet aggregation inhibitors excl. heparin C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent > C190801 - P2Y12 Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[1].
N-Jasmonoyltyrosine
C21H27NO5 (373.18891320000006)
N-jasmonoyl-L-tyrosine
C21H27NO5 (373.18891320000006)
4-((((9H-FLUOREN-9-YL)METHOXY)CARBONYL)(METHYL)AMINO)BENZOIC ACID
1,3,4,6-Tetra-o-Acetyl-2-Azido-2-Deoxy-Alpha-D-Mannopyranose
C14H19N3O9 (373.11212439999997)
[(2R,3R,4R,5R)-3,4,6-triacetyloxy-5-azidooxan-2-yl]methyl acetate
C14H19N3O9 (373.11212439999997)
2-[(1-Acetyl-2-oxopropyl)thio]-N-cyclohexyl-1H-benzimidazole-1-carboxamide
alpha-Hydroxy-alpha-phenylbenzeneacetic acid (3-endo)-8-azabicyclo[3.2.1]oct-3-yl ester hydrochloride
C21H24ClNO3 (373.14446240000007)
1,1-DIPHENYL-3-(PIPERIDIN-1-YL)PROPYL METHANESULFONATE
C21H27NO3S (373.17115520000004)
Urea, N-[2-(1H-benzimidazol-2-yl)ethyl]-N-(3-cyanophenyl)-N-cyclopentyl- (9CI)
3,3-bis(4-hydroxy-3,5-dimethylphenyl)-1H-indol-2-one
C24H23NO3 (373.16778480000005)
Sepimostat
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor Sepimostat (FUT-187 free base) exhibits neuroprotective activity via NR2B N-methyl-D-aspartate receptor antagonism at the Ifenprodil-binding site of the NR2B subunit. Sepimostat inhibits the Ifenprodil binding with a Ki value of 27.7?μM[1].
3-N-BOC-AMINO-1-[2-AMINO-1-(4-TRIFLUOROMETHYL-PHENYL)-ETHYL]-PYRROLIDINE
N N-BIS((R)-(+)-1-PHENYLETHYL)PHTHALAMI&
C24H23NO3 (373.16778480000005)
4-(P-TOLUENESULFONYLAMINO)PHENYLBORONIC ACID PINACOL ESTER
C19H24BNO4S (373.15190140000004)
1,3,4,6-tetra-o-acetyl-2-azido-2-deoxy-alpha-d-galactopyranose
C14H19N3O9 (373.11212439999997)
Urea, N-[2-(1H-benzimidazol-2-yl)ethyl]-N-(4-cyanophenyl)-N-cyclopentyl- (9CI)
5-[bis(1-isocyanato-1-cyclohexa-2,4-dienyl)methyl]-5-isocyanato-cyclohexa-1,3-diene
amineptine hydrochloride
C22H28ClNO2 (373.18084580000004)
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents
N-(5-CHLORO-3-((4-(DIETHYLAMINO)-2-METHYLPHENYL)IMINO)-4-METHYL-6-OXOCYCLOHEXA-1,4-DIEN-1-YL)ACETAMIDE
Urea, N-[2-[(3-cyano-6,8-dimethyl-2-quinolinyl)amino]ethyl]-N-(phenylmethyl)- (9CI)
(1s,2s)-2-(anthracene-2,3-dicarboximido)cyclohexanecarboxylic acid
N-(3,4,6-TRI-O-ACETYL-β-D-GLUCOPYRANOSYL) PIPERIDINE
(1R,2R)-2-(Anthracene-2,3-dicarboximido)cyclohexanecarboxylic Acid
1,3,4,6-tetra-o-acetyl-2-azido-2-deoxy-alpha-d-glucopyranose
C14H19N3O9 (373.11212439999997)
2-[2-[4-(1H-Indol-3-yl)-1-piperidinyl]ethyl]-1H-isoindole-1,3(2H)-dione
Methylene Blue trihydrate
C16H24ClN3O3S (373.12268240000003)
D004791 - Enzyme Inhibitors
4-methyl-N-[2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]benzenesulfonamide
C19H24BNO4S (373.15190140000004)
(3-BOC-AMINO-AZETIDIN-1-YL)-NAPHTHALEN-2-YL-ACETICACID
C20H27N3O4 (373.20014620000006)
1-BOC-4-[CARBOXY-(1H-INDOL-2-YL)-METHYL]-[1,4]DIAZEPANE
C20H27N3O4 (373.20014620000006)
2-amino-1-[3-(hydroxymethyl)cyclobutyl]-4-(3-phenylmethoxyphenyl)pyrrole-3-carbonitrile
Benzyl 4-(4-(2,3-dihydroxypropoxy)-phenyl)butylcarbamate
C21H27NO5 (373.18891320000006)
3-(Toluene-4-sulfonylaMino)phenylboronic acid, pinacol ester
C19H24BNO4S (373.15190140000004)
(4-BENZOYL-PHENYL)-PHOSPHONICACIDDIETHYLESTER
C20H27N3O4 (373.20014620000006)
tert-Butyl 2-(2-(3-(trifluoromethyl)phenoxy)ethyl)piperidine-1-carboxylate
C19H26F3NO3 (373.18646820000004)
1-[(E)-(Dimethylamino)methylene]-3-tritylthiourea
C23H23N3S (373.16125980000004)
tert-butyl 4-[2-amino-1-[4-(trifluoromethyl)phenyl]ethyl]piperazine-1-carboxylate
1H-Benzimidazole,2-[1-[[1-(phenylmethyl)-1H-tetrazol-5-yl]methyl]-4-piperidinyl]-(9CI)
4-O-benzyl 2-O-ethyl 3-(2-ethoxy-2-oxoethyl)-5-methyl-1H-pyrrole-2,4-dicarboxylate
1,3,4,6-Tetra-O-acetyl-2-azido-2-deoxy-beta-D-glucopyranose
C14H19N3O9 (373.11212439999997)
DIBENZYL (1-METHYL-4-OXOIMIDAZOLIDIN-2-YLIDENE)PHOSPHORAMIDATE
C18H20N3O4P (373.1191370000001)
N-[2-(Dansylamino)ethyl]maleimide
C18H19N3O4S (373.10962140000004)
5-(2-Cyclopropyl-1-(3-fluorophenyl)-2-oxoethyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate
S1RA hydrochloride
S1RA (E-52862) hydrochloride is an orally active and selective sigma-1 receptor (σ1R) antagonist with a Ki value of 17 nM. S1RA hydrochloride shows good selectivity against σ2R (Ki >1000 nM). S1RA hydrochloride is a human 5-HT2B receptor antagonist with an IC50 value of 4.7 μM. S1RA hydrochloride inhibits neuropathic pain and activity-induced spinal sensitization[1][2].
1,2,3,4-Tetra-O-acetyl-6-azido-6-deoxy-a-D-glucopyranose
C14H19N3O9 (373.11212439999997)
N,N-BIS((S)-1-PHENYLETHYL) PHTHALAMIC ACID
C24H23NO3 (373.16778480000005)
6-Azido-6-deoxy-D-galactopyranose 1,2,3,4-tetraacetate
C14H19N3O9 (373.11212439999997)
(2S,4R)-1-(TERT-BUTOXYCARBONYL)-4-(4-(TRIFLUOROMETHYL)BENZYL)PYRROLIDINE-2-CARBOXYLIC ACID
C18H22F3NO4 (373.15008480000006)
1-Azido-2,3,4,6-tetra-O-acetyl-beta-D-glucose
C14H19N3O9 (373.11212439999997)
2,3,4,6-TETRA-O-ACETYL-ALPHA-D-GLUCOPYRANOSYL AZIDE
C14H19N3O9 (373.11212439999997)
(4s)-(-)-4,5-dihydro-2-[2-(diphenylphosphino)phenyl]-4-isopropyloxazole
(R)-(+)-2-[2-(Diphenylphosphino)phenyl]-4-isopropyl-2-oxazoline
TERT-BUTYL 5-(6-HYDROXYNAPHTHALEN-2-YL)-2,2-DIMETHYL-1,3-DIOXAN-5-YLCARBAMATE
C21H27NO5 (373.18891320000006)
2,3,4,6-Tetra-O-acetyl-beta-D-galactopyranosyl azide
C14H19N3O9 (373.11212439999997)
Ritobegron
C21H27NO5 (373.18891320000006)
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists
5-(7-Chloro-2-((S)-1-cyclopropyl-ethyl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl)-isoxazole-3-carboxylic acid dimethylamide
C19H20ClN3O3 (373.11931200000004)
Proroxan hydrochloride
C21H24ClNO3 (373.14446240000007)
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs
2-methyl-5-[4-[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]butyl]-1,3-dioxane-2-carboxylic Acid
C21H27NO5 (373.18891320000006)
5-(3-((1-amino-3,3-dimethyl-1-oxobutan-2-yl)carbamoyl)-1H-indol-1-yl)pentanoicacid
C20H27N3O4 (373.20014620000006)
[1-acetyl-3,6-bis(tert-butylsulfanyl)-4-methyl-3,6-dihydro-2H-pyridin-2-yl] acetate
6-[(Z)-Amino(imino)methyl]-N-[3-(cyclopentyloxy)phenyl]-2-naphthamide
1-[(3S)-5-Phenyl-3-thiophen-2-YL-3H-1,4-benzodiazepin-2-YL]azetidin-3-OL
C22H19N3OS (373.12487640000006)
(1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime
Hydroxy(oxo)(3-{[(2Z)-4-[3-(1H-1,2,4-triazol-1-ylmethyl)phenyl]pyrimidin-2(5H)-ylidene]amino}phenyl)ammonium
Tetra(imidazole)diaquacopper (I)
C12H22CuN8O2+2 (373.11616219999996)
Lobeline hydrochloride
C22H28ClNO2 (373.18084580000004)
Lobeline (α-Lobeline) hydrochloride is a brain-penetrant nicotinic receptor agonist. Lobeline hydrochloride increases dopamine (DA) release by inhibiting DA uptake into synaptic vesicles, and altering presynaptic DA storage. Lobeline hydrochloride is effective in smoking cessation[1][2]. Lobeline hydrochloride, a nicotinic receptor agonist, acting as a potent antagonist at both α3β2 and α4β2 neuronal nicotinic receptor subtypes.
Motesanib
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
3-(3,4-Dimethoxyphenyl)-6-(3-propan-2-ylphenyl)-[1,2,4]triazolo[4,3-a]pyridine
3-(1-(4-Chlorobenzyl)-5-fluoro-3-methylindol-2-yl)-2,2-dimethylpropanoic acid
(10S,12R)-10-(2-methylbut-3-en-2-yl)-1,3,14-triazapentacyclo[10.9.0.02,10.04,9.015,20]henicosa-4,6,8,15,17,19-hexaene-13,21-dione
(2R,4E)-2-amino-5-({[(2S,3R)-2-hydroxy-3-(1H-indol-3-yl)butanamido]methanimidoyl}amino)pent-4-enoate
C18H23N5O4 (373.17499580000003)
(2S,3R,4S)-3-ethenyl-4-(2-oxoethyl)-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2H-pyran-5-carboxylate
C16H21O10- (373.11346660000004)
(E,2S)-2-amino-5-[[amino-[[(2S,3R)-2-hydroxy-3-(1H-indol-3-yl)butanoyl]amino]methylidene]amino]pent-4-enoic acid
C18H23N5O4 (373.17499580000003)
(2S)-2-[[2-[(1R,2S)-2-[(Z)-5-hydroxypent-2-enyl]-3-oxocyclopentyl]acetyl]amino]-3-phenylpropanoic acid
C21H27NO5 (373.18891320000006)
Hydroxydesmethyltetrahydropiperine sulfate
C16H23NO7S (373.11951680000004)
6-methyl-2-[[(4-methylanilino)-oxomethyl]amino]-5,7-dihydro-4H-thieno[2,3-c]pyridine-3-carboxylic acid ethyl ester
Survector
C22H28ClNO2 (373.18084580000004)
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents
4-(4-methoxycarbonylphenyl)-1,2,6-trimethyl-4H-pyridine-3,5-dicarboxylic acid dimethyl ester
1,3-diethyl-6-methyl-N-(2-methylphenyl)-2-oxo-5-benzimidazolesulfonamide
4-(3-hydroxyphenyl)-1-(2-oxolanylmethyl)-4H-pyridine-3,5-dicarboxylic acid dimethyl ester
6-(1,3-benzodioxol-5-yl)-N-[(3-fluorophenyl)methyl]-4-quinazolinamine
5-[4-(4-Hydroxyphenyl)piperazin-1-yl]sulfonyl-1,3-dihydroindol-2-one
C18H19N3O4S (373.10962140000004)
2-(4-Methoxyphenyl)-4-(4-methoxyphenyl)imino-1-benzopyran-6-ol
1-[Tert-butyl-[(3,5-dimethylphenyl)-oxomethyl]amino]-3-(4-chlorophenyl)urea
1-[8-Chloro-4-(1-naphthalenyl)-3,3a,4,9b-tetrahydrocyclopenta[c]quinolin-5-yl]ethanone
C24H20ClNO (373.12333400000006)
6-(2-Pyrrolidinone-5-yl)-(-)-epicatechin
A natural product found in Actinidia arguta.
8-(2-Pyrrolidinone-5-yl)-(-)-epicatechin
A natural product found in Actinidia arguta.
8-oxoresolvin D1(1-)
A polyunsaturated fatty acid anion that is the conjugate base of 8-oxoresolvin D1, obtained by deprotonation of the carboxy group; major species at pH 7.3.
3-methyl-N-{4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl}benzamide
17-oxoresolvin D1(1-)
A polyunsaturated fatty acid that is the conjugate base of 17-oxoresolvin D1, obtained by deprotonation of the carboxy group; major species at pH 7.3.
2-[3-(2-furanylmethyl)-2,4-dioxo-6,7,8,9-tetrahydro-5H-cyclohepta[2,3]thieno[2,4-b]pyrimidin-1-yl]acetamide
C18H19N3O4S (373.10962140000004)
4-[2-[(E)-(2,5-dioxo-1-phenylimidazolidin-4-ylidene)methyl]pyrrol-1-yl]benzoic acid
C21H15N3O4 (373.10625100000004)
10-Methyl-3-(2-phenylethyl)-2-propan-2-ylpyrimido[4,5-b]quinoline-4,5-dione
1-Butyl-2,4-dioxo-7-thiophen-2-yl-5-pyrido[2,3-d]pyrimidinecarboxylic acid ethyl ester
C18H19N3O4S (373.10962140000004)
(3aR)-10,10-dimethyl-2-(4-methylbenzyl)-4,9-dihydro-3aH-imidazo[1,5-b]-carboline-1,3-quinone
N-[(3-chlorophenyl)methyl]-6-phenyl-3-(2-pyridinyl)-1,2,4-triazin-5-amine
C21H16ClN5 (373.10941660000003)
5-[1-[(3,5-Dimethoxyphenyl)methylamino]propylidene]-1-prop-2-enyl-1,3-diazinane-2,4,6-trione
C19H23N3O5 (373.16376280000003)
4-[[3-oxo-2-(3-pyridinyl)-1H-isoindol-1-yl]amino]benzoic acid ethyl ester
N-[2-(4-methoxyphenoxy)ethyl]-5-(4-morpholinyl)-2-nitroaniline
C19H23N3O5 (373.16376280000003)
butyl 4-[5-[(E)-(ethylcarbamothioylhydrazinylidene)methyl]furan-2-yl]benzoate
2-Phenylbutanoic acid [2-oxo-2-(2-phenylanilino)ethyl] ester
C24H23NO3 (373.16778480000005)
(2,6-Difluorophenyl)-[4-(5-fluoro-2-methyl-1-benzimidazolyl)-1-piperidinyl]methanone
4-[3-(1,3-Benzodioxol-5-ylmethylamino)-7-methyl-2-imidazo[1,2-a]pyridinyl]phenol
1-(4-chlorophenyl)-N-(2-furanylmethyl)-N-[[1-(2-methylbutan-2-yl)-5-tetrazolyl]methyl]methanamine
6-[[[1-(2-methoxy-5-methylphenyl)-5-tetrazolyl]thio]methyl]-N2,N2-dimethyl-1,3,5-triazine-2,4-diamine
(15S)-10,10-Dimethyl-13-[(4-methylphenyl)methyl]-8,11,13-triazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(9),2,4,6-tetraene-12,14-dione
(15R)-10,10-Dimethyl-13-[(3-methylphenyl)methyl]-8,11,13-triazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(9),2,4,6-tetraene-12,14-dione
(15S)-10,10-Dimethyl-13-[(3-methylphenyl)methyl]-8,11,13-triazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(9),2,4,6-tetraene-12,14-dione
(15S)-10,10-Dimethyl-13-[(2-methylphenyl)methyl]-8,11,13-triazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(9),2,4,6-tetraene-12,14-dione
(15R)-10,10-Dimethyl-13-[(2-methylphenyl)methyl]-8,11,13-triazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(9),2,4,6-tetraene-12,14-dione
(4E,8E)-10-(4,6-dihydroxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4,8-dimethyldeca-4,8-dienoate
4-Nitrobenzoic acid (3,3,7,8-tetramethyl-1,5-dihydro-[1,3]dioxepino[5,6-c]pyridin-7-ium-9-yl) ester
4-[2-[[1-(2-Oxolanylmethyl)-5-phenyl-2-imidazolyl]thio]ethyl]morpholine
C20H27N3O2S (373.18238820000005)
N-[4-[2-methyl-4-(2-methylpropyl)-5-oxo-2-oxolanyl]-2-thiazolyl]benzohydrazide
2-[[2,3-dihydro-1,4-benzodioxin-3-yl(oxo)methyl]amino]-6-methyl-5,7-dihydro-4H-thieno[2,3-c]pyridine-3-carboxamide
C18H19N3O4S (373.10962140000004)
2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[(4-methoxyphenyl)sulfonylamino]-2-oxanyl]acetic acid methyl ester
C16H23NO7S (373.11951680000004)
2-[[(1R,5S)-7-[4-[(E)-2-phenylethenyl]phenyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]methyl]-1,3-thiazole
C23H23N3S (373.16125980000004)
(2R,3R,3aS,9bS)-3-(hydroxymethyl)-2-(piperidine-1-carbonyl)-1-propanoyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one
C20H27N3O4 (373.20014620000006)
2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[(4-methoxyphenyl)sulfonylamino]-2-oxanyl]acetic acid methyl ester
C16H23NO7S (373.11951680000004)
2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[(4-methoxyphenyl)sulfonylamino]-2-oxanyl]acetic acid methyl ester
C16H23NO7S (373.11951680000004)
2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[(4-methoxyphenyl)sulfonylamino]-2-oxanyl]acetic acid methyl ester
C16H23NO7S (373.11951680000004)
3,5-dimethyl-4-[[(1R,5S)-7-[4-[(E)-prop-1-enyl]phenyl]-3,6-diazabicyclo[3.1.1]heptan-6-yl]sulfonyl]-1,2-oxazole
(4-fluorophenyl)-[(1R,5S)-7-[4-(3-pyridinyl)phenyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]methanone
[(2S,3S)-6-methylsulfonyl-3-phenyl-1-(2-pyridinylmethyl)-1,6-diazaspiro[3.3]heptan-2-yl]methanol
2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[(4-methoxyphenyl)sulfonylamino]-2-oxanyl]acetic acid methyl ester
C16H23NO7S (373.11951680000004)
2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[(4-methoxyphenyl)sulfonylamino]-2-oxanyl]acetic acid methyl ester
C16H23NO7S (373.11951680000004)
2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[(4-methoxyphenyl)sulfonylamino]-2-oxanyl]acetic acid methyl ester
C16H23NO7S (373.11951680000004)
2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[(4-methoxyphenyl)sulfonylamino]-2-oxanyl]acetic acid methyl ester
C16H23NO7S (373.11951680000004)
(2R,3R,4S)-3-[4-(1-cyclohexenyl)phenyl]-4-(hydroxymethyl)-1-[oxo(2-pyridinyl)methyl]-2-azetidinecarbonitrile
(2S,3S,4R)-3-[4-(1-cyclohexenyl)phenyl]-4-(hydroxymethyl)-1-[oxo(2-pyridinyl)methyl]-2-azetidinecarbonitrile
(2S,3S,3aR,9bR)-3-(hydroxymethyl)-2-[oxo(1-piperidinyl)methyl]-1-(1-oxopropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one
C20H27N3O4 (373.20014620000006)
[(2S,3R)-1-methylsulfonyl-3-phenyl-6-(2-pyridinylmethyl)-1,6-diazaspiro[3.3]heptan-2-yl]methanol
(3Z)-3-[(E)-1-Hydroxy-2,4-dimethyloct-6-enylidene]-5-[hydroxy-(4-hydroxyphenyl)methyl]pyrrolidine-2,4-dione
C21H27NO5 (373.18891320000006)
2-[(1,5-Dimethyl-3-oxo-2-phenylpyrazol-4-yl)diazenyl]-3-(2-methylphenyl)-3-oxopropanenitrile
Prasugrel
B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AC - Platelet aggregation inhibitors excl. heparin C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent > C190801 - P2Y12 Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[1].
7-oxoresolvin D2(1-)
A docosanoid anion that is the conjugate base of 7-oxoresolvin D2, obtained by deprotonation of the carboxy group; major species at pH 7.3.
16-oxoresolvin D2(1-)
A docosanoid anion that is the conjugate base of 16-oxoresolvin D2, obtained by deprotonation of the carboxy group; major species at pH 7.3.
[1-(5-Fluoropentyl)-1H-indol-3-yl](4-methylnaphthalen-1-yl)methanone
MIND4-19
C22H19N3OS (373.12487640000006)
MIND4-19 is a potent SIRT2 inhibitor with an IC50 value of 7.0 μM. MIND4-19 can be used for researching Huntington's disease[1].
N6-(4-Hydroxybenzyl)adenosine
N6-(4-Hydroxybenzyl)adenosine is a inhibitor of platelet aggregation induced in vitro by collagen and their activity range was demonstrated (IC50: 6.77-141 μM). IC50 value: 6.77-141 μM Target: P2Y12receptor Anti-aggregation activity of N6-(4-Hydroxybenzyl)adenosine could involve an interaction with the P2Y12receptor binding site. N6-(4-Hydroxybenzyl)adenosine is a inhibitor of platelet aggregation induced in vitro by collagen and their activity range was demonstrated (IC50: 6.77-141 μM). IC50 value: 6.77-141 μM Target: P2Y12receptor Anti-aggregation activity of N6-(4-Hydroxybenzyl)adenosine could involve an interaction with the P2Y12receptor binding site.
NADPH oxidase-IN-1
C20H27N3O2S (373.18238820000005)
NADPH oxidase-IN-1 is an orally active NADPH oxidase (Nox) inhibitor, related with neuronal inflammation. NADPH oxidase-IN-1 can cross the blood-brain barrier (BBB), inhibits Nox2 and Nox4 with IC50s of 1.9 μM and 2.47 μM, respectively. NADPH oxidase-IN-1 suppresses pro-inflammatory cytokines production and LPS-mediated microglial migration, also has in vivo efficacy[1].
Osavampator
Osavampator (TAK-653) is a AMPA receptor positive allosteric modulator. Osavampator selectively binds to AMPA-R in a glutamate-dependent manner and induces Ca2+ influx in hGluA1i CHO cells (EC50 = 3.3 μM). Osavampator improves learning and memory in many models. Osavampator is can be used for the research of depressive disorders[1][2]. Osavampator (TAK-653) is a AMPA receptor positive allosteric modulator. Osavampator selectively binds to AMPA-R in a glutamate-dependent manner and induces Ca2+ influx in hGluA1i CHO cells (EC50 = 3.3 μM). Osavampator improves learning and memory in many models. Osavampator is can be used for the research of depressive disorders[1][2].